In collaboration with Institut Pasteur de Lille and the Center for Infection & Immunity of Lille (CIIL), Physiogenex now delivers its diet-induced obese NASH hamster as a unique metabolic comorbidities model infected with SARS-Cov-2, to accelerate the development of COVID-19 therapies.
As in human obese/type 2 diabetic patients with comorbidities (NASH and heart failure), SARS-CoV-2 infection induces greater disease severity in the Physiogenex free choice diet-induced obese NASH hamster.
To see how you could move forward quickly with your novel therapies targeting COVID-19 and its severe forms, check our brief model description and contact us for more information here.
PHYSIOGENEX LAUNCHES A NEW PRECLINICAL MODEL TO BATTLE COVID-19
